Group 1 - The company Garden Biotech (300401.SZ) has a subsidiary, Garden Pharmaceuticals, that produces antibiotic-related formulations, although the revenue contribution from these products is relatively low [2] - Investors are advised to make rational investment decisions and be aware of investment risks [2] Group 2 - The inquiry about the company's antibiotic products was made on an investor interaction platform [2] - The response indicates that while the company does have relevant products, they do not significantly impact overall revenue [2]

Core Viewpoint - The company Garden Bio (300401) has developed a proprietary chemical synthesis process for Vitamin B6, which features fewer reaction steps and milder conditions, allowing for cost reduction while maintaining yield [1] Group 1: Production Methods - The company’s Vitamin B6 production utilizes a self-developed chemical synthesis process that is efficient and cost-effective [1] - The company is also working on a project for an annual production of 10,000 tons of L-Alanine through fermentation, which is a key raw material for Vitamin B6 production [1]

证券日报网讯1月27日，花园生物（300401）在互动平台回答投资者提问时表示，公司饲料级胆固醇目 前国内暂未产生营收。饲料级胆固醇作为饲料添加剂，下游主要为预混料、饲料生产厂商等。 ...

证券日报网讯1月27日，花园生物（300401）在互动平台回答投资者提问时表示，截至2026年1月20日， 公司股东总户数为26019户。 ...

Core Viewpoint - The company has received a new product certificate for feed additives from the Ministry of Agriculture and Rural Affairs of China, which will restrict other production and import applications for this new feed and feed additive for a monitoring period of five years [1] Group 1 - The company is now authorized to produce a new feed additive, which may enhance its market position in the agricultural sector [1] - The monitoring period of five years will prevent other companies from applying for production or import registration of the same new feed and feed additive, potentially reducing competition [1]

格隆汇1月27日丨花园生物(300401.SZ)在投资者互动平台表示，公司饲料级胆固醇目前国内暂未产生营 收。饲料级胆固醇作为饲料添加剂，下游主要为预混料、饲料生产厂商等。 ...

Core Viewpoint - The company has not yet generated revenue from its feed-grade cholesterol product, which is intended as an additive for animal feed [2]. Group 1: Company Information - The company, Huayuan Biological (花园生物), confirmed that its feed-grade cholesterol has not yet produced revenue domestically [2]. - The primary downstream customers for feed-grade cholesterol include premix and feed manufacturers [2].

Group 1 - The core viewpoint of the article highlights the target price increases for several listed companies, with significant growth potential identified by brokerage firms [1][3] - The companies with the highest target price increases include Baili Tianheng at 368.30%, Luoyang Molybdenum at 37.88%, and Sanqi Interactive Entertainment at 29.53%, representing the chemical pharmaceutical, industrial metals, and gaming industries respectively [1][3] - A total of 23 listed companies received brokerage recommendations on January 26, with companies like Jianda Co., Shouhua Gas, and Huayuan Bio receiving one recommendation each [3] Group 2 - On January 26, one company had its rating upgraded, specifically Hualu Hengsheng, which was raised from "Hold" to "Buy" by Tianfeng Securities [4][6] - The only company receiving a first-time coverage rating on January 26 was Boshi Jie, which was given a "Strong Buy" rating by China Merchants Securities [6][7]

（文章来源：证券日报） 证券日报网讯 1月23日，花园生物在互动平台回答投资者提问时表示，截至2026年1月20日，公司股东 总户数为26019户。 ...

Group 1 - The core viewpoint of the article is that Huayuan Biological clarified its product offerings, stating that it sells feed-grade cholesterol and does not involve premixes [2] Group 2 - The company engaged with investors through an interactive platform to address inquiries regarding its product line [2] - The clarification aims to provide transparency about the nature of the products sold by the company [2]